Clinical Trials Logo
  1. Home
  2. Pertussis/Whooping Cough
  3. NCT05234229

Influenza and Pertussis Vaccination Status of Women in Immediate Postpartum and Caregivers — COVAGRIP  

Influenza Viral Infections Clinical Trial

Official title:
Influenza and Pertussis Vaccination Status of Women in Immediate Postpartum and Caregivers in the Maternity Hospital of Nancy

Clinical Trial Summary

Pertussis is a bacterial respiratory infection caused by Bordetella pertussis. Highly contagious, it is potentially serious and even fatal in infants under 6 months of age. The immunity acquired through vaccination is very limited in time, requiring regular booster shots. There is a passive protection of the newborn by the maternal-fetal transmission of maternal antibodies, but it is brief. The infant's first vaccination is given at 2 months of age and immunity is not acquired until the second injection at 4 months of age. The booster at 11 months of age is essential to prolong this immunity. In order to protect infants under 6 months of age, France has recommended since 2004 the cocooning strategy, which consists of vaccinating people likely to be in close contact with the infant during this period. This vaccination is therefore proposed to adults who are planning to have children, to the entourage of pregnant women, and in the immediate post-partum period for the mother (and people who were not vaccinated during pregnancy). This strategy was put in place following the international recommendation of a forum of scientific experts, the Global Pertussis Initiative. In France, vaccination against pertussis is not currently recommended during pregnancy. There is no contraindication to vaccination during pregnancy and it is recommended in many countries. Influenza is a viral respiratory infection caused by Myxovirus influenzae, which is highly contagious. In France, vaccination against influenza is recommended for pregnant women, regardless of the trimester of pregnancy. It is also recommended for the entourage of infants under 6 months of age with risk factors for severe influenza. There are few recent data in the scientific literature regarding influenza and pertussis vaccination coverage among pregnant or postpartum women in France. In addition, the COVID19 pandemic has recently reopened the debate on vaccination of the general population and caregivers. Knowing the current status of vaccination coverage among pregnant women and caregivers, their knowledge and fears regarding vaccination could help improve the information provided by healthcare staff.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05234229
Study type Observational
Source Central Hospital, Nancy, France
Contact
Status Completed
Phase
Start date March 1, 2022
Completion date October 30, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT05869201 - Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine Phase 2/Phase 3
Recruiting NCT06123936 - Impact on Influenza Vaccination Rates of a Telephone Text Message Recall From the Attending Physician N/A
Completed NCT02103023 - Intradermal Influenza Vaccine in the Young Phase 3
Completed NCT04623047 - Infection Watch Study
Not yet recruiting NCT02465190 - Effectiveness of Trivalent Inactivated Influenza Maternal Vaccination Among Pregnant Women and Their Newborns in South Africa N/A
Completed NCT05620953 - Severe Acute Respiratory Infections (SARI) in Belgium (2011-2020)
Recruiting NCT05739474 - Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children Phase 3
Active, not recruiting NCT05794412 - Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study
Recruiting NCT05557539 - Hypothesizing the Genesis of Infectious Diseases and Epidemics Through an Integrated Systems Biology Approach N/A
Completed NCT03813966 - Nasal Swab Home Collection Kit (NSHC Kit) Study
Terminated NCT05105191 - Analytical Performances and Clinical Impact of the Roche Cobas® Liat Influenza A/B & RSV Assay in the Management of Adult and Pediatric Patients Attending the Emergency Room N/A
Not yet recruiting NCT06247059 - Reducing Respiratory Virus Transmission in Bangladeshi Classrooms N/A
Not yet recruiting NCT06175468 - Evaluate the Efficacy and Safety of "Formosa 1-Breath Free (NRICM101) " in Subjects With the Symptoms of COVID-19 or Influenza-like Disease Phase 3
Active, not recruiting NCT01666782 - Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy Phase 2
Completed NCT05507567 - Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model Phase 2
Active, not recruiting NCT04998344 - An Effectiveness Trial to Evaluate Protection of Children and Pregnant Women by Influenza Vaccine in Rural Bangladesh Phase 4